NCT06236789Recruiting
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 1 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used as standard treatment for patients with metastatic castration-resistant prostate cancer. However, there is insufficient research on salvage therapy for patients with metastatic castration-resistant prostate cancer who have failed standard treatment. In this study, the investigators will evaluate the effectiveness and safety of ifosfamide in castration-resistant prostate cancer by analyzing the treatment outcomes of patients who received ifosfamide/mesna treatment as salvage therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 24 Jan 2024
- Start date
- Nov 2016
- Primary completion date
- Nov 2026
- Lead sponsor
- Yonsei University
- Diseases
- Prostate cancer
- NCT number
- NCT06236789
What you commit to
- Study type: Observational
- Planned participants: 60
- From Nov 2016 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients without previous docetaxel exposure
- Patients previously exposed to ifosfamide
Other illness
- Patients with other primary cancers diagnosed within 3 years other than prostate cancer
- Patients with a history of organ transplantation
- Hormone sensitive prostate cancer
- Patients without evaluable disease based on RECIST 1.1
Other
- ECOG 3 or higher
- Patients without available PSA level
Who the study is looking for
- 19 years and older adult male
- Patients with histologically confirmed prostate cancer
- Castration-resistant prostate cancer
- ECOG 2 or less
- Patients with previous docetaxel exposure
- Patients with available PSA level
- Patients with evaluable disease based on RECIST 1.1
Age in the registry: 19 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.